Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia.
Bruno S, Bandini L, Patuelli A, Robustelli V, Venturi C, Mancini M, Forte D, De Santis S, Monaldi C, Grassi A, Chiurumbolo G, Paolini S, Cristiano G, Papayannidis C, Sartor C, Nanni J, Ottaviani E, Curti A, Cavo M, Soverini S. Bruno S, et al. Among authors: soverini s. Front Oncol. 2021 Sep 30;11:728613. doi: 10.3389/fonc.2021.728613. eCollection 2021. Front Oncol. 2021. PMID: 34660293 Free PMC article.
Molecular therapy for multiple myeloma.
Martinelli G, Tosi P, Ottaviani E, Soverini S, Tura S. Martinelli G, et al. Among authors: soverini s. Haematologica. 2001 Sep;86(9):908-17. Haematologica. 2001. PMID: 11532618 Review.
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Martinelli G, Amabile M, Giannini B, Terragna C, Ottaviani E, Soverini S, Saglio G, Rosti G, Baccarani M. Martinelli G, et al. Among authors: soverini s. Haematologica. 2002 Jul;87(7):688-94; discussion 694. Haematologica. 2002. PMID: 12091118
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation.
Soverini S, Cavo M, Cellini C, Terragna C, Zamagni E, Ruggeri D, Testoni N, Tosi P, De Vivo A, Amabile M, Grafone T, Ottaviani E, Giannini B, Cangini D, Bonifazi F, Neri A, Fabris S, Tura S, Baccarani M, Martinelli G. Soverini S, et al. Blood. 2003 Sep 1;102(5):1588-94. doi: 10.1182/blood-2002-12-3789. Epub 2003 May 1. Blood. 2003. PMID: 12730120 Free article. Clinical Trial.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I, Rosti G, Amabile M, Poerio A, Soverini S, Cilloni D, Testoni N, Abruzzese E, Montefusco E, Ottaviani E, Iuliano F, Russo D, Gobbi M, Alimena G, Martino B, Terragna C, Pane F, Saglio G, Baccarani M, Martinelli G. Iacobucci I, et al. Among authors: soverini s. J Clin Oncol. 2006 Jan 20;24(3):454-9. doi: 10.1200/JCO.2005.03.2011. J Clin Oncol. 2006. PMID: 16421422
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Iacobucci I, Saglio G, Rosti G, Testoni N, Pane F, Amabile M, Poerio A, Soverini S, Bassi S, Cilloni D, Bassan R, Breccia M, Lauria F, Izzo B, Merante S, Frassoni F, Paolini S, Montefusco E, Baccarani M, Martinelli G; GIMEMA Working Party on Chronic Myeloid Leukemia. Iacobucci I, et al. Among authors: soverini s. Clin Cancer Res. 2006 May 15;12(10):3037-42. doi: 10.1158/1078-0432.CCR-05-2574. Clin Cancer Res. 2006. PMID: 16707599 Clinical Trial.
184 results